NCT04482894

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or High-Risk Myelodysplastic Syndrome: Randomized Phase II Study

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 105 (estimated)
• Sponsor: University of Virginia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Detailed description

Participants in this study will be randomized to either an intervention group or a standard of care group. Participants in the intervention group will participate in regular visits with a palliative (or supportive) care specialist, while participants in the standard of care group will only see palliative care specialists if the clinician requests a referral. All participants will be asked to complete monthly questionnaires regarding their general well-being. Participants have a greater chance of being assigned to the intervention group than to the standard of care group. On average, in every 5 people randomized, 3 will be randomized to the intervention and 2 will be randomized to standard of care.

Conditions

• Leukemia, Acute
• AML, Adult
• ALL, Adult
• Myelodysplastic Syndromes

Interventions

Type	Name	Description
OTHER	Palliative Care Visits	Regular visits with a palliative (supportive) care specialist

Timeline

• Start date: 2020-08-19
• Primary completion: 2025-05-09
• Completion: 2026-04-01
• First posted: 2020-07-23
• Last updated: 2025-05-15

Locations

1 site across 1 country: United States